Pharming Group N.V. Files 6-K with Press Release

TL;DR

Pharming Group (PHAR) filed a 6-K on 4/8, likely with news. Check Exhibit 99.1.

AI Summary

Pharming Group N.V. filed a Form 6-K on April 8, 2024, to furnish a press release dated April 8, 2024, as Exhibit 99.1. The filing does not contain specific financial figures or operational details beyond the submission of this press release.

Why It Matters

This filing indicates Pharming Group N.V. is providing updated information to the SEC, likely containing important business or financial developments for investors.

Risk Assessment

Risk Level: low — This filing is a routine submission of a press release and does not contain inherently risky information.

Key Players & Entities

• Pharming Group N.V. (company) — Registrant
• 001-39822 (company) — SEC File Number
• April 8, 2024 (date) — Filing Date and Press Release Date

FAQ

Filing Documents

• pharmingped1completionofen.htm (6-K) — 38KB
• logo_greyxoriginalx.jpg (GRAPHIC) — 112KB
• logo_pharmingxoriginal.jpg (GRAPHIC) — 18KB
• 0001828316-24-000012.txt ( ) — 206KB

Forward-looking Statements

Forward-looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", anticipate'', believe'', could'', estimate'', expect'', goals'', intend'', may'', "milestones", objectives'', outlook'', plan'', probably'', project'', risks'', "schedule", seek'', should'', target'', will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2023 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred t

View Full Filing

View this 6-K filing on SEC EDGAR